Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

Botta, Cirino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.287
EU - Europa 976
AS - Asia 238
AF - Africa 14
SA - Sud America 10
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.535
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.245
IT - Italia 579
SG - Singapore 144
GB - Regno Unito 89
DE - Germania 65
IE - Irlanda 63
CA - Canada 40
RU - Federazione Russa 40
CN - Cina 26
EE - Estonia 19
HK - Hong Kong 18
FI - Finlandia 16
FR - Francia 14
BE - Belgio 13
UA - Ucraina 13
IN - India 12
SE - Svezia 11
CH - Svizzera 10
JP - Giappone 9
ES - Italia 7
UZ - Uzbekistan 6
CI - Costa d'Avorio 5
KR - Corea 5
NL - Olanda 5
RO - Romania 5
TR - Turchia 5
AT - Austria 4
GR - Grecia 4
NZ - Nuova Zelanda 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
BR - Brasile 3
CL - Cile 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
LK - Sri Lanka 2
NO - Norvegia 2
RS - Serbia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
HR - Croazia 1
IR - Iran 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 3.535
Salva come PNG Salva come JPEG
Città #
Chandler 375
Fairfield 276
Ashburn 250
Medford 122
Singapore 115
Wilmington 115
Altamura 114
Palermo 83
Princeton 79
Lawrence 77
Cambridge 76
Houston 64
San Diego 64
Dublin 60
Woodbridge 45
Santa Clara 37
Milan 34
Seattle 33
Toronto 33
London 30
Ann Arbor 29
Rome 21
Tallinn 19
Beijing 14
Brussels 13
Kilburn 12
New York 12
Saint Petersburg 11
Catania 10
Florence 10
Ludwigshafen am Rhein 10
Naples 10
Lappeenranta 9
Noto 9
San Paolo di Civitate 9
Abbiategrasso 8
Boardman 8
Chicago 8
Tokyo 8
Turin 8
Vicenza 8
West Jordan 8
Edinburgh 7
Helsinki 7
Hounslow 7
Munich 7
Phoenix 7
Forest City 6
Piscataway 6
Abidjan 5
Bari 5
Castrovillari 5
Central 5
Central District 5
Dallas 5
Frankfurt am Main 5
Norwalk 5
Redwood City 5
Sciara 5
Stockholm 5
Auckland 4
Bremen 4
Caserta 4
Catanzaro 4
Clearwater 4
Los Angeles 4
Moscow 4
Mumbai 4
Novara 4
Romainville 4
Washington 4
Apo 3
Aversa 3
Bonn 3
Cagliari 3
Cavallino 3
Cingoli 3
Corropoli 3
Guangzhou 3
Hong Kong 3
Kerken 3
Kiev 3
Kowloon 3
Melilli 3
Mendicino 3
Mountain View 3
Ponzano Veneto 3
Shanghai 3
Springfield 3
Verona 3
Vienna 3
Wandsworth 3
Addis Ababa 2
Agrigento 2
Alcamo 2
Amsterdam 2
Andover 2
Ankara 2
Annaba 2
Beograd 2
Totale 2.561
Salva come PNG Salva come JPEG
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 128
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 102
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 82
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 77
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 76
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 69
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 65
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 60
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 58
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 58
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 57
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 57
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 56
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 54
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 53
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 52
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 52
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 51
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 51
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 51
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 51
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 50
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 47
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 47
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 47
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 47
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 46
miR-22 suppresses DNA ligase III addiction in multiple myeloma 46
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 46
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 46
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 46
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 45
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 45
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 45
Mouse models of multiple myeloma: Technologic platforms and perspectives 45
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 45
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 45
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 45
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 44
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 44
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 44
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients 44
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma 43
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 43
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 43
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 43
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 43
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 42
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 42
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 42
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 42
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 42
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 42
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 42
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 42
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 42
Immunologic characterization of COVID-19 patients with hematological cancer 41
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 41
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 41
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 40
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 38
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 38
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 38
Immunotherapy of colorectal cancer: New perspectives after a long path 38
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities 37
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 37
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 37
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 37
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 36
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 36
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells 36
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment 35
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 35
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 34
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 34
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 34
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 33
Immunologic microenvironment and personalized treatment in multiple myeloma 31
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 31
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 30
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients 30
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma 29
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 29
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 28
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 27
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 27
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 25
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice 25
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing 24
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 24
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 22
Multiple Myeloma in 2023 Ways: From Trials to Real Life 18
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 18
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance 14
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma 9
null 3
Totale 4.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.134
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021774 0 0 0 0 0 0 0 0 9 4 19 742
2021/2022912 56 131 28 27 23 76 44 43 100 153 61 170
2022/20231.378 109 247 94 112 146 182 21 137 152 18 118 42
2023/2024766 46 116 57 122 68 75 69 56 23 30 10 94
2024/2025302 55 148 96 3 0 0 0 0 0 0 0 0
Totale 4.132